论文部分内容阅读
与常规抗心律失常药物相比,β—受体阻断剂(BB)对扩张型心肌病(DCM)患者的室性心律失常效果明显,成功地抑制了85%患者的室性早搏,并逐渐提高了左室短轴缩短率和一年存活率。DCM 患者,因严重室性心律失常和猝死的发病率很高。虽然抑制室性心律失常可减少猝死的发生,但是直到今天,对DCM进行抗心律失常治疗的作用仍有争议。BB 具有抑制室性心律失常的作用,特别是对体内儿茶酚胺水平高的患者更为有效。DCM 患者其交感一儿茶酚胺系统活动加强,因此BB 可有效抑制室性心律失常。然而,值得疑虑的是,心衰或DCM 患者不能
Compared with conventional antiarrhythmic drugs, β-blockers (BB) have a significant effect on ventricular arrhythmias in patients with dilated cardiomyopathy (DCM), successfully suppressing ventricular premature beats in 85% of patients and gradually Improved left ventricular fractional shortening and one-year survival. Patients with DCM have a high incidence of severe ventricular arrhythmias and sudden death. Although inhibition of ventricular arrhythmias can reduce the incidence of sudden death, the role of antiarrhythmic therapy in DCM remains controversial until now. BB has the role of inhibiting ventricular arrhythmias, especially in patients with high catecholamine levels in vivo more effective. DCM patients with sympathetic catecholamine system activity, so BB can effectively inhibit ventricular arrhythmias. However, it is worth noting that heart failure or DCM patients can not